In mouse colon cancer xenografts, a combination of B37 (apo-IDO1 inhibitor) with vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor apatinib induced more extensive anticancer effects than monotherapies [26]. This evidence concerns the gene KDR and colonic neoplasm.